Browsing: Feature Stories
Quantum computing has the potential to revolutionize how new drugs are developed. With the ability to take on challenges too…
ENB Therapeutics’ Orphan Drug, Endothelin Receptor Type B Target for Resistant Cancers
Last week, President and Co-Founder Sumayah Jamhal presented her company, ENB Therapeutics, at the 2023 Immuno-Oncology 360 Degree Conference in…
A rare genetic respiratory disease affecting the tiny structures in the lungs that filter air is the target of promising…
Value-based care is the cornerstone of improved quality outcomes for patients. Treating patients is no longer just about fixing the…
After a bullish 2021, characterized by a flow of M&A deals and IPOs, this year company valuations were in correction,…
A New Lymphoid Technology That Accelerates Immune Reconstitution in Hematopoietic Stem Cell Transplantation
Smart Immune is a clinical-stage biotechnology startup headquartered in France, developing a thymus-empowered T-cell therapy platform called ProTcell Platform. The…
Advanced neuroimaging techniques that can detect disease-linked proteins in the brain could be the key to quickly and accurately diagnosing…
Chronic kidney disease (CKD) affects more than 1 in 7 U.S. adults and approximately 2 in 1,000 Americans live with…
One company’s approach to breaking barriers within the TME to overcome recalcitrant cancers. Earlier this month, a preview of patient-derived…
Cala Heath, Inc. is a bioelectronic medicine company that develops non-invasive neuromodulation therapies for chronic diseases through wearable devices. Their…
Company
Subscribe to Updates
Get the latest news from Biotech Metropolitan Women.
Biotech Metropolitan Women ©2018-2023